Company intelligence
Oncidium foundation
Promote, support and accelerate the development of radiotheranostics for cancer care, worldwide.
About Oncidium foundation
The Oncidium foundation was created in 2011 to promote the development of nuclear medicine therapy through the dissemination of reliable and complete information for patients. Radiotherapeutics and radiotheranostics represent a new class of drugs that can be used for patient suffering from incurable cancers. The Foundation's priority include promoting the awareness among patients and physicians, investing in research and scholarship, supporting and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice and improving access to patients.
Verified activity
Signals from Oncidium foundation
6 published signals
Presence & Recognition
Oncidium foundation participated in the Latin American Nuclear Olympiad 2026, which focused entirely on Radiotheranostics.
Reported by Oncidium foundation
Partnerships
Oncidium foundation established a partnership with Hackapower Oficial to advance radiotheranostics.
Reported by Oncidium foundation
Presence & Recognition
Oncidium foundation hosted the first Virtual Radiotheranostics Summit in collaboration with the MEDICAID CANCER FOUNDATION.
Reported by Oncidium foundation
Research & Knowledge
Oncidium foundation published a Survivornet Connect discussion examining whether PSMA-targeted radioligand therapy could deliver greater benefit when introduced earlier
Reported by Michael Crosby
Presence & Recognition
Oncidium foundation participated in an interview with patient Levi at the 40th Brazilian Congress of Nuclear Medicine on the ¹⁷⁷Lu-PSMA treatment journey.
Reported by Oncidium foundation
Presence & Recognition
Oncidium foundation hosted the Virtual Radiotheranostics Summit, which brought together world-class experts and an audience that kept the Q&A going until the very last minute.
Reported by Oncidium foundation